<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>synbiointel.com — Synthetic Biology News</title>
    <link>https://synbiointel.com</link>
    <description>News, funding, and analysis for the synbio and synbio industry.</description>
    <language>en-us</language>
    <atom:link href="https://synbiointel.com/feeds/market" rel="self" type="application/rss+xml"/>
    <ttl>60</ttl>
    
    <item>
      <title><![CDATA[Sumitomo Mitsui Dumps 217K Twist Bio Shares Worth $11M]]></title>
      <link>https://synbiointel.com/news/sumitomo-mitsui-sells-twist-bioscience-shares</link>
      <guid isPermaLink="true">https://synbiointel.com/news/sumitomo-mitsui-sells-twist-bioscience-shares</guid>
      <pubDate>Wed, 15 Apr 2026 09:52:54 GMT</pubDate>
      <description><![CDATA[Japanese trust giant reduces Twist position by 19% as DNA synthesis sector faces headwinds]]></description>
      <category>market</category>
    </item>
    <item>
      <title><![CDATA[Evercore Raises Editas Price Target to $15 on CRISPR Pipeline]]></title>
      <link>https://synbiointel.com/news/evercore-raises-editas-price-target-15-crispr-pipeline</link>
      <guid isPermaLink="true">https://synbiointel.com/news/evercore-raises-editas-price-target-15-crispr-pipeline</guid>
      <pubDate>Tue, 14 Apr 2026 07:54:57 GMT</pubDate>
      <description><![CDATA[Evercore maintains Buy rating for Editas Medicine with increased $15 target amid CRISPR program momentum]]></description>
      <category>market</category>
    </item>
    <item>
      <title><![CDATA[Goldman Raises Generate Biomedicines Target to $26]]></title>
      <link>https://synbiointel.com/news/goldman-raises-generate-biomedicines-target-26</link>
      <guid isPermaLink="true">https://synbiointel.com/news/goldman-raises-generate-biomedicines-target-26</guid>
      <pubDate>Sat, 11 Apr 2026 02:36:11 GMT</pubDate>
      <description><![CDATA[Goldman Sachs maintains Buy rating on Generate Biomedicines, lifting price target to $26 amid AI protein design momentum]]></description>
      <category>market</category>
    </item>
    <item>
      <title><![CDATA[Editas Medicine Stock Drops Amid Clinical Trial Setbacks]]></title>
      <link>https://synbiointel.com/news/editas-medicine-stock-drops-clinical-trial-setbacks</link>
      <guid isPermaLink="true">https://synbiointel.com/news/editas-medicine-stock-drops-clinical-trial-setbacks</guid>
      <pubDate>Sun, 29 Mar 2026 03:54:02 GMT</pubDate>
      <description><![CDATA[CRISPR pioneer faces investor concerns over delayed trials and competitive pressure from newer base editing platforms]]></description>
      <category>market</category>
    </item>
    <item>
      <title><![CDATA[Absci Reports Q4 2025 Results: AI Drug Discovery Under Scrutiny]]></title>
      <link>https://synbiointel.com/news/absci-q4-2025-earnings-ai-drug-discovery</link>
      <guid isPermaLink="true">https://synbiointel.com/news/absci-q4-2025-earnings-ai-drug-discovery</guid>
      <pubDate>Mon, 23 Mar 2026 12:48:18 GMT</pubDate>
      <description><![CDATA[Absci's Q4 2025 results test investor confidence in AI-powered generative biology platforms amid drug development challenges]]></description>
      <category>market</category>
    </item>
    <item>
      <title><![CDATA[Absci Trades at $2.86 Ahead of Critical Q4 Earnings]]></title>
      <link>https://synbiointel.com/news/absci-trades-286-q4-earnings-march-24</link>
      <guid isPermaLink="true">https://synbiointel.com/news/absci-trades-286-q4-earnings-march-24</guid>
      <pubDate>Thu, 19 Mar 2026 14:03:17 GMT</pubDate>
      <description><![CDATA[Absci Corporation trades at $2.86 ahead of Q4 earnings on March 24, with investors watching for partnership updates and platform progress.]]></description>
      <category>market</category>
    </item>
  </channel>
</rss>